Abstract As the coronavirus 2019 (COVID-19) pandemic marches unrelentingly, more
patients with cardiac arrhythmias are emerging due to the effects of the virus on the …

This virtual workshop was convened by the National Heart, Lung, and Blood Institute, in
partnership with the Office of Strategic Coordination of the Office of the National Institutes of …

Background We are facing the outburst of coronavirus disease 2019 (COVID-19) defined as
a serious, multisystem, disorder, including various neurological manifestations in its …

During the course of the COVID-19 pandemic, obesity has been shown to be an
independent risk factor for high morbidity and mortality. Obesity confers poor outcomes in …

Device therapy is a nonpharmacological approach that presents a crucial advancement for
managing patients with atrial fibrillation (AF) and heart failure with preserved ejection …

In patients with heart failure (HF), the neuroendocrine systems of the sympathetic nervous
system (SNS), the renin–angiotensin–aldosterone system (RAAS) and the arginine …

In the era of the coronavirus disease 2019 (COVID-19) pandemic, acute cardiac injury (ACI),
as reflected by elevated cardiac troponin above the 99th percentile, has been observed in …

The introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors as a new and
effective class of therapeutic agents for type 2 diabetes (T2D) preventing the reabsorption of …

Background Recent studies reported a long-lasting effect of COVID-19 infection that extends
beyond the active disease and disrupts various body systems besides the respiratory …

Among various neuropsychiatric disorders, depression and anxiety are commonly
encountered in patients with heart failure (HF), reported in≥ 50% of patients attending a HF …